Thor Medical specializes in the production and supply of alpha-particle emitters for cancer therapy, focusing on the use of radionuclide therapy (RNT) and radioligand therapy (RLT). Their innovative production process involves the separation of naturally occurring radioactive decay products from thorium (Th-232), which allows for the creation of high-quality alpha emitters. This proprietary technology is designed to be both cost-effective and environmentally friendly, ensuring a reliable supply of these therapeutic radioisotopes for the radiopharmaceutical industry.

One of the key products offered by Thor Medical is Lead-212 (Pb-212), a therapeutic radioisotope derived from the decay of Thorium-228. Pb-212 is particularly notable for its short half-life, making it suitable for precision cancer treatments. Thor Medical has recently entered into a supply agreement with a leading pharmaceutical company for the provision of Pb-212 for pre-clinical studies, highlighting their capability to meet the demands of major players in the industry. The company’s commitment to advancing cancer treatment technologies is further demonstrated by their strategic agreements and the establishment of pilot facilities in Herøya for the production of these isotopes.

Norway

Thor Medical's primary market is to supply alpha emitters to suppliers and developers of innovative drugs targeting indications with high unmet medical needs, including any medical products and equipment. Going forward, the main business focus will be to refine the production technology, secure customer qualification and commitments, mature the manufacturing concept, and secure regulatory approvals and permits for industrialization.

Thor Medical

Company Details